Start: June 9, 2021
End: November 2025
Enrollment: 450
This Phase 2 study, called Together, will test the safety and effectiveness of the experimental drug bepranemab to improve memory and other cognitive functions in older adults with mild cognitive impairment or early-stage Alzheimer's disease. In the first phase of the study, participants will be randomly assigned to one of three groups; to receive an IV infusion of a placebo or one of two doses of the study drug for 20 months. In the next phase, those participants already receiving the study drug will continue to receive the same drug dosage. The participants receiving the placebo will be randomly assigned to one of two doses of the study drug for six months. All participants will undergo PET and MRI brain imaging at the start of the study and after 14 and 20 months. They will also complete a variety of cognitive tests and provide blood and cerebrospinal fluid (optional) samples. Researchers will also measure changes in cognitive and daily functioning, changes in the levels of proteins associated with Alzheimer's, and track the concentration of the study drug in the blood. In addition, the researchers will evaluate the safety of the drug during treatment and for one year after the last dose.
Minimum Age: 50 Years
Maximum Age: 80 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information and to enroll, visit the Together study website.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Arizona | |
---|---|
Ah0003 50305
Sun City, AZ 85351
Recruiting
|
|
California | |
Ah0003 50428
Fresno, CA 93710
Recruiting
|
|
Ah0003 50431
Fullerton, CA 92835
Recruiting
|
|
Ah0003 50442
Irvine, CA 92614
Recruiting
|
|
Ah0003 50458
Long Beach, CA 90807
Recruiting
|
|
Ah0003 50450
Palo Alto, CA 94303
Recruiting
|
|
Ah0003 50452
Pasadena, CA 91105
Recruiting
|
|
Ah0003 50447
San Diego, CA 92123
Recruiting
|
|
Ah0003 50434
Santa Ana, CA 92705
Recruiting
|
|
Connecticut | |
Ah0003 50422
New Haven, CT 06510
Recruiting
|
|
Ah0003 50467
New Haven, CT 06510
Recruiting
|
|
Ah0003 50421
Stamford, CT 06905
Recruiting
|
|
Florida | |
Ah0003 50465
Atlantis, FL 33462
Recruiting
|
|
Ah0003 50449
Aventura, FL 33180
Recruiting
|
|
Ah0003 50435
Boca Raton, FL 33487
Recruiting
|
|
Ah0003 50437
Boynton Beach, FL 33437
Recruiting
|
|
Ah0003 50430
Delray Beach, FL 33445
Recruiting
|
|
Ah0003 50429
Fort Myers, FL 33912
Recruiting
|
|
Ah0003 50436
Hialeah, FL 33016
Recruiting
|
|
Ah0003 50426
Maitland, FL 32751
Recruiting
|
|
Ah0003 50427
Miami, FL 33172
Recruiting
|
|
Ah0003 50478
Naples, FL 34105
Recruiting
|
|
Ah0003 50464
Ocoee, FL 34761
Recruiting
|
|
Ah0003 50438
Pensacola, FL 32502
Recruiting
|
|
Ah0003 50457
Port Orange, FL 32127
Recruiting
|
|
Ah0003 50454
Tampa, FL 33613
Recruiting
|
|
Ah0003 50444
West Palm Beach, FL 33407
Recruiting
|
|
Ah0003 50476
West Palm Beach, FL 33409
Recruiting
|
|
Ah0003 50446
Westchester, FL 33155
Recruiting
|
|
Georgia | |
Ah0003 50479
Decatur, GA 30033
Recruiting
|
|
Kentucky | |
Ah0003 50439
Lexington, KY 40504
Recruiting
|
|
Massachusetts | |
Ah0003 50445
Braintree, MA 02184
Recruiting
|
|
Ah0003 50453
Newton, MA 02459
Recruiting
|
|
Minnesota | |
Ah0003 50448
Saint Paul, MN 55130
Recruiting
|
|
New Jersey | |
Ah0003 50420
Neptune, NJ 07753
Recruiting
|
|
Ohio | |
Ah0003 50451
Cincinnati, OH 45219
Recruiting
|
|
Ah0003 50255
Columbus, OH 43210
Recruiting
|
|
Oregon | |
Ah0003 50443
Portland, OR 97210
Recruiting
|
|
Rhode Island | |
Ah0003 50423
East Providence, RI 02914
Recruiting
|
|
Tennessee | |
Ah0003 50455
Cordova, TN 38018
Recruiting
|
|
Texas | |
Ah0003 50380
Houston, TX 77478
Recruiting
|
|
Virginia | |
Ah0003 50424
Fairfax, VA 22031
Recruiting
|
|
Ah0003 50432
Norfolk, VA 23507
Recruiting
|
|
Washington | |
Ah0003 50440
Bellevue, WA 98007
Recruiting
|
Lead: UCB Biopharma SRL
Source: ClinicalTrials.gov ID: NCT04867616